Trial Information

Summary: Research Study for those with mild Cystic Fibrosis

UVa Health System, seeks those with Cystic Fibrosis (CF) ages 5 years and older for research study called TIGER-1.

The purpose of the Tiger-1 study is to evaluate the safety and effectiveness of an investigational compound for mild CF lung disease. Study involves taking an investigational drug (or placebo) by nebulizer 3 times a day. Participants will have as many as 10 office visits and study procedures include lung function tests, chest x-rays, blood and urine tests, physical exams and questionnaires.

For more information or to see if you qualify to enroll, please contact:
Robin Kelly-Saunders
(434)243-2876
IRB-HSR # 12591

Principal Investigator: Deborah Froh, MD



www.healthsystem.virginia.edu/clinical_trials

Contact:

Robin L Kelly-Saunders RN
University of Virginia
School of Medicine
Allergy/Pulmonary/Cystic Fibrosis, Pediatrics
Charlottesville, VA 22908
Telephone: 434-243-2876
Fax: 434-924-8388
Email:

Profile Page: University of Virginia, Charlottesville, VA

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:39:54 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA